Agenus Inc. (AGEN) has been initiated today with coverage from the research analysts at Dawson James. Dawson James begins this new coverage of AGEN with an initial price target set at $2 dollars and positions their performance outlook of AGEN as “buy.” AGEN is down during intraday trading despite opening high this morning.
Agenus conducts business in the Health Care sector, particularly the Biotechnology industry. Agenus is currently trading below its 50 & 200-day moving averages and 2011 is currently a down year for the company. Notably, AGEN’s price action has been mostly whipsaw since February.
Agenus Inc. is a company that is focused on the development and commercialization of technologies to treat cancers and infectious diseases, primarily based on immunological approaches. As of January 6, 2011, they changed their name from Antigenics Inc. to Agenus Inc. to more accurately reflect their existing product pipeline. The company has market capitalization of $105,000,000 and 112,654,000 shares outstanding. AGEN has a 52-week high of $1.16 with the low being 73 cents.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.